Explicyte News & Press

Announcements, partnership news, and milestones from Explicyte — what we're building, who we're working with, and where the science is heading.

Reserve Your Atera Slot for 2026

News Jul 15, 2026

Reserve Your Atera Slot for 2026

Smarter Xenium: More Biology per Slide, More Value per Sample

News May 19, 2026

Smarter Xenium: More Biology per Slide, More Value per Sample

Explicyte earns ISO 13485 and ISO 9001 certifications for clinical tissue biomarker development & testing in oncology trials

Press release Feb 18, 2026

Explicyte earns ISO 13485 and ISO 9001 certifications for clinical tissue biomarker development & testing in oncology trials

A second Xenium: Explicyte doubles down on single-cell spatial transcriptomics

Press release Dec 3, 2025

A second Xenium: Explicyte doubles down on single-cell spatial transcriptomics

Single-Cell Spatial Biology: Explicyte Becomes the First 10x Genomics-Certified Service Provider in France for Xenium studies

Press release Nov 4, 2025

Single-Cell Spatial Biology: Explicyte Becomes the First 10x Genomics-Certified Service Provider in France for Xenium studies

Inducing Tertiary Lymphoid Structures (TLS): our IHF data released in Cancer Cell (MSKCC collaboration)

News Aug 29, 2025

Inducing Tertiary Lymphoid Structures (TLS): our IHF data released in Cancer Cell (MSKCC collaboration)

Cure51 Partners with Explicyte for Spatial Analysis of Exceptional Cancer Survivor Samples from 40 Countries

Press release Jun 26, 2025

Cure51 Partners with Explicyte for Spatial Analysis of Exceptional Cancer Survivor Samples from 40 Countries

Explicyte Becomes the First Immuno-Oncology CRO in Europe Equipped with the 10x Xenium Platform for Single-Cell Spatial Transcriptomics

News Oct 16, 2024

Explicyte Becomes the First Immuno-Oncology CRO in Europe Equipped with the 10x Xenium Platform for Single-Cell Spatial Transcriptomics

Ultra-trail: 330 km in the Alpes to support cancer immunotherapy research

News Jun 25, 2024

Ultra-trail: 330 km in the Alpes to support cancer immunotherapy research

Translational Research in Cancer Immunotherapy: 5 Key Findings

News Jun 7, 2024

Translational Research in Cancer Immunotherapy: 5 Key Findings

TROP2: A Strong Predictor of Resistance to Immunotherapy in Lung Cancer

News Dec 22, 2023

TROP2: A Strong Predictor of Resistance to Immunotherapy in Lung Cancer

New Avenues in Cancer Immunotherapy: A Conversation with Pr Antoine Italiano

News Sep 21, 2023

New Avenues in Cancer Immunotherapy: A Conversation with Pr Antoine Italiano

A Partnership Between Explicyte and Bergonié Institute Fuels Major Breakthroughs in Precision Immunotherapy

News Jun 20, 2023

A Partnership Between Explicyte and Bergonié Institute Fuels Major Breakthroughs in Precision Immunotherapy

Back from ASCO 2023: Interview with Alban Bessede

News Jun 16, 2023

Back from ASCO 2023: Interview with Alban Bessede

Explicyte Becomes an Olink®-Certified Service Provider to Expand Its Biomarker Discovery Capabilities

News May 31, 2022

Explicyte Becomes an Olink®-Certified Service Provider to Expand Its Biomarker Discovery Capabilities

Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology

Press release Mar 10, 2022

Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology

CONDOR Consortium Awarded RHU Funding to Advance Precision Medicine and Immunotherapy in Soft Tissue Sarcomas

Press release Jan 27, 2022

CONDOR Consortium Awarded RHU Funding to Advance Precision Medicine and Immunotherapy in Soft Tissue Sarcomas

Explicyte Becomes a Certified NanoString Partner to Advance Digital Spatial Profiling in Oncology

Press release Dec 10, 2020

Explicyte Becomes a Certified NanoString Partner to Advance Digital Spatial Profiling in Oncology